# Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

> **NCT02830932** · PHASE1 · COMPLETED · sponsor: **Vaxart** · enrollment: 66 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** VXA-RSV-f Tablets (high dose)
- **OTHER:** VXA Placebo Tablets
- **BIOLOGICAL:** VXA-RSV-f Tablets (low dose)

## Key facts

- **NCT ID:** NCT02830932
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-22
- **Primary completion:** 2016-09-16
- **Final completion:** 2017-09-20
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02830932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02830932, "Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02830932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*